{
    "nctId": "NCT00344318",
    "officialTitle": "To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar\u2122, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age",
    "inclusionCriteria": "* Male or female between, and including, 6-12 weeks (42 to 90 days) of age at the time of the first vaccination.\n* Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol\n* Written informed consent obtained from the parent or guardian of the subject.\n* Free of obvious health problems as established by medical history and clinical examination before entering into the study.\n* Born after a gestation period between 36 and 42 weeks.\n* Must have minimum age of 6 Weeks\n* Must have maximum age of 12 Weeks",
    "exclusionCriteria": "* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3.\n* Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations\n* History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b diseases.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.\n* History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease.\n* Acute disease at the time of enrolment\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical\n* A family history of congenital or hereditary immunodeficiency.\n* Major congenital defects or serious chronic illness.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the active phase of the study."
}